ArticleCell reports. Medicine2025
The serum metabolome serves as a diagnostic biomarker and discriminates patients with melanoma from healthy individuals.
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Serum metabolomic signatures of cutaneous malignancies identified by untargeted profiling.Medicine and pharmacy reports · 2026Article
- Lipidomics in Melanoma: Insights into Disease Progression and Therapeutical Targets.International journal of molecular sciences · 2026Review
- Untargeted serum metabolomics reveals metabolic signatures distinguishing basal cell carcinoma risk groups: an exploratory analysis.Medicine and pharmacy reports · 2026Article
- Cutaneous Melanoma in the Context of Aging.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is a deadly cancer with increasing incidence and mortality rates, and biomarkers for diagnosis are urgently needed. The impact of the microbiome, genetic factors, and immunologic markers on disease outcomes is described, but a comprehensive serum metabolome profiling is missing. The serum metabolome of patients with melanoma might be valuable to identify potential biomarkers. We present an untargeted metabolomics analysis in an exploratory cohort (87 patients with melanoma), an independent validation cohort (37 additional patients with melanoma featuring late-stage tumors), and 18 healthy control individuals, revealing striking differences. We identify and validate six serum metabolites that can predict the diagnosis of melanoma with an area under the curve (AUC) >0.9544 in advanced-stage melanoma. The AUC of our lead biomarker, muramic acid, is 0.964, 0.908, and 0.9936 in patients with stage I (n = 22), stage II (n = 67), and advanced melanoma (n = 86), respectively. In summary, we identify potentially very powerful diagnostic biomarkers for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.